Effect of Psychosomatic Symptom Intervention on Psychosomatic Symptoms During Initial Treatment in Patients With Differentiated Thyroid Cancer: A Single-blind Randomized Controlled Trial.

Cancer NursApr 23, 2025 (epub)

Shuhua Luo, Xiaoxiao Wei, Jiaxin Zhao et al.

✦ AI-curated · Sources linked

In 30 seconds

This single-blind randomized controlled trial evaluated a 12-week psychosomatic symptom intervention in 84 patients with differentiated thyroid cancer recruited from one cancer hospital. Compared with usual care, the intervention group had lower anxiety and depression at post-intervention and follow-up assessments (P < .001). Thyroid-stimulating hormone target attainment was 59.5% in the intervention group versus 26.2% in controls (P = .008); self-management efficacy and shoulder joint function also differed significantly between groups (P < .001). The findings suggest potential psychological and physical benefits during initial treatment.

Key findings

  • Anxiety and depression were significantly lower in the intervention group at both post-intervention and follow-up assessments (P < .001).
  • Thyroid-stimulating hormone target attainment was 59.5% with intervention versus 26.2% in controls (P = .008).
  • Self-management efficacy and shoulder joint function differed significantly between groups (P < .001).

Why it matters

Initial treatment for differentiated thyroid cancer can involve psychological and physical symptoms. This trial suggests that a structured psychosomatic intervention may address both, alongside a higher thyroid-stimulating hormone target attainment rate. These outcomes are relevant to recovery and self-care, although the findings come from a single-hospital study and should be interpreted in that context.

What to keep in mind

Participants were recruited from one cancer hospital; the abstract does not report the duration of follow-up.

Source

Published in Cancer Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.